• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Ora Inc

A close image of a blue eye
CRO

Ophthalmic CRO Ora kept in ocular clinical trial pact with Axim

Axim Biotechnologies, which explores medical uses of cannabis, has decided to continue contracting Ora to manage its drug R&D activities and clinical trials on glaucoma and dry eye.
Angus Liu Mar 29, 2017 2:19pm
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy